2026 Annual Shareholders' Meeting Results
News Release STOCK EXCHANGE LISTINGS: NEW ZEALAND (FPH), AUSTRALIA (FPH) 25 August 2026 Results of 2026 Annual Shareholders’ Meeting At Fisher & Paykel Healthcare Corporation Limited’s Annual Shareholders’ Meeting, held in Auckland and online today, shareholders were asked to vote on seven ordinary resolutions. As required by NZX Listing Rule 6.1, all voting was conducted by a poll. The ordinary resolutions passed were: Resolution 1: To elect Anna Curzon as a Director. Resolution 2: To authorise the Directors to fix the fees and expenses of the auditor. Resolution 3: To approve an increase to the maximum aggregate annual remuneration payable to non-executive directors. Resolution 4: To approve the grant of discretionary long term variable remuneration instruments to Lewis Gradon. Resolution 5: To approve the 2025 Performance Share Rights Plan – North America. Resolution 6: To approve the 2025 Share Option Plan – North America. Resolution 7: To approve the Employee Share Rights Plan – North America. Details of the total number of votes cast in person, online or by a proxy holder are: Resolution Votes: Resolution 1: To elect Anna Curzon as a Director. For: 439,332,659 (99.88%); Against: 514,296 (0.12%); Abstain: 27,182 Resolution 2: To authorise the Directors to fix the fees and expenses of the auditor. For: 429,021,432 (97.54%); Against: 10,823,333 (2.46%); Abstain: 29,372 Resolution 3: To approve an increase to the maximum aggregate annual remuneration payable to non-executive directors. For: 352,605,905 (80.47%); Against: 85,601,037 (19.53%); Abstain: 112,884 Resolution 4: To approve the grant of discretionary long term variable remuneration instruments to Lewis Gradon. For: 429,735,033 (97.98%); Against: 8,874,134 (2.02%); Abstain: 706,131 Resolution 5: To approve the 2025 Performance Share Rights Plan – North America. For: 432,722,619 (98.55%); Against: 6,386,217 (1.45%); Abstain: 765,307 Resolution 6: To approve the 2025 Share Option Plan – North America. For: 431,054,743 (98.16%); Against: 8,063,344 (1.84%); Abstain: 756,056 Resolution 7: To approve the Employee Share Rights Plan – North America. For: 438,797,705 (99.93%); Against: 326,148 (0.07%); Abstain: 750,290 As at the commencement of the meeting, Fisher & Paykel Healthcare Corporation Limited had 587,302,790 total number of voting shares on issue. Authority for this announcement Raelene Leonard General Counsel & Company Secretary +64 9 610 4803 raelene.leonard@fphcare.co.nz Date of release through MAP 25 August 2026 About Fisher & Paykel Healthcare Fisher & Paykel Healthcare is a leading designer, manufacturer and marketer of products and systems for use in acute and chronic respiratory care, surgery and the treatment of obstructive sleep apnea. The company’s products are sold in over 120 countries worldwide. For more information, visit our website www.fphcare.com. Contacts Media Karen Knott GM Corporate Communications karen.knott@fphcare.co.nz +64 21 713 911 Investors Dan Adolph Head of Investor Relations daniel.adolph@fphcare.co.nz +64 22 511 4050